Greenwich LifeSciences, Inc.
Quick facts
Phase 3 pipeline
- GLSI-100 · Oncology
GLSI-100 is an autologous dendritic cell vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Greenwich LifeSciences, Inc.
What is Greenwich LifeSciences, Inc.'s pipeline?
Greenwich LifeSciences, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include GLSI-100.
Related
- Sector hub: All tracked pharma companies